论文部分内容阅读
目的观察替吉奥单药治疗老年晚期非小细胞肿瘤(NSCLC)患者的疗效及不良反应。方法对31例II-IB-IV期老年NSCLC患者应用替吉奥(S-1)单药化疗[60mg/(m2.d),口服1～14d)21d为1个周期。2个周期后分别按实体瘤疗效评价标准(RECIST)和美国国立癌症研究所(NCI)常见毒性反应标准评价不良反应,同时评估生活质量改善指标。结果本组31例患者中,完全缓解(CR)0例,部分缓解(PR)10例,稳定(SD)13例,进展(PD)8例,有效(CR+PR)率为:32.3%;临床受益(CR+PR+SD)率为:74.2%。中位无疾病进展生存(PFS)期为5.1个月。中位生存(OS)期为7.8个月,1年生存率为30.6%。患者不良反应主要表现为白细胞减少为主的骨髓抑制,白细胞减少I-II度发生率为38.7%(12/31),III-IV度为6.5%(2/31)。血小板减少I-II°发生率为19.3%(6/31),III°为3.2%(1/31)无IV度减少发生。结论采用替吉奥弹药治疗老年晚期NSCLC患者疗效好,不良反应轻,安全,可作为老年晚期NSCLC患者的一线治疗方案。
Objective To observe the efficacy and adverse reactions of tizoglu monotherapy in elderly patients with advanced non-small cell tumor (NSCLC). Methods A total of 31 patients with stage II-IB-IV NSCLC aged 1 to 21 days were treated with S-1 monotherapy (60 mg / (m2.d) orally for 1 to 14 days). After 2 cycles, adverse reactions were evaluated according to RECIST and NCI common toxicological response criteria, respectively, and quality of life indicators were also evaluated. Results Among the 31 patients, there were 0 complete remission (CR), 10 partial remission (PR), 13 stable (SD) and 8 progressive (PD) patients. The effective rate of CR + PR was 32.3%. The clinical benefit (CR + PR + SD) rate was 74.2%. The median progression-free survival (PFS) was 5.1 months. The median OS was 7.8 months and the 1-year OS was 30.6%. The main adverse reactions of patients were leukopenia-predominant myelosuppression. The incidence of leukopenia I-II was 38.7% (12/31) and III-IV was 6.5% (2/31). The incidence of thrombocytopenia with I-II ° was 19.3% (6/31) and III ° was 3.2% (1/31) with no IV degree reduction. Conclusion The treatment of elderly patients with advanced non-small cell lung cancer NSCLC with good efficacy, mild adverse reactions, and safety, can be used as a first-line treatment for elderly patients with advanced non-small cell lung cancer.